Talus Biosciences, a Seattle, WA-based drug discovery company, raised $11.2M in Seed+ funding.
The round was led by Two Bear Capital, with participation from WRF Capital, NFX, YC Continuity Fund, Funders Club VC, and BoxOne Ventures.
The company intends to use the funds to advance its therapeutic programs, which include Brachyury-driven cancers and an undruggable transcription factor implicated in prostate cancer. It will also accelerate the expansion of its proprietary multiplexed assays for the rational modulation of transcription factors (MARMOT) platform.
Founded in 2020 by Alex Federation, PhD, and Lindsay Pino, PhD, Talus Bio is a drug discovery and development company focused on therapeutics that target previously undruggable transcription factors. Its proprietary therapeutics discovery platform, MARMOT (Multiplexed Assays for the Rational Modulation Of Transcription Factors), integrates AI, proteomics, synthetic chemistry, and computational biology to engineer and interrogate drugs, proteins, and genomics at scale.
MARMOT leverages new AI models trained on Talus Bio’s dataset for transcription factor activity, to allow scientists to rapidly identify optimal candidates from billions of compounds, replacing high-throughput screens. With MARMOT, machine learning models discover and optimize modulators for any given transcription factor target, enabling the massive acceleration of discovery screening in live, unmodified human cells where targets fold and function properly.
FinSMEs
20/08/2024